(MedPage Today) — CHICAGO — An investigational monoclonal antibody drug targeting the PD-1 ligand on T cells was a winner in a phase II rheumatoid arthritis (RA) trial.
Twelve weeks of treatment with the agent, called rosnilimab, led to a…
Source link : https://www.medpagetoday.com/meetingcoverage/acr/118229
Author :
Publish date : 2025-10-30 15:22:00
Copyright for syndicated content belongs to the linked Source.
